Table 1.
Signaling proteins phosphorylated/dephosphorylated by AVR and NAVR on ANG II and AVP stimulation
| Protein Name | Protein Symbol | Phospho Site | Role in Renal Physiology and Pathophysiology | AVR+ANG II % CFC |
AVR+AVP % CFC |
NAVR+AVP % CFC |
|---|---|---|---|---|---|---|
| Ataxia telangiectasia mutated | ATM | S1981 | Cellular response to increased osmolality/double strand break pathway (55) |
−21 | 8 | 25 |
| Protein-serine kinase Cβ2 | PKCb2 | T641 | reabsorption (44) | 106 | 28 | 36 |
| Protein-serine kinase Cγ | PKCg | T674 | reabsorption (44) | 23 | 21 | 50 |
| cAMP-dependent protein-serine kinase catalytic subunit β |
PKA Cb | S338 | Water balance/vasopressin-regulated water channels (39) | 108 | 7 | 10 |
| cAMP-dependent protein-serine kinase regulatory type 2 subunit α |
PKA R2a | S98 | Water balance/vasopressin-regulated water channels (39) | −20 | −6 | 68 |
| cAMP-dependent protein-serine kinase regulatory type 2 subunit β |
PKA R2b | S114 | Water balance/vasopressin-regulated water channels (39) | 39 | 43 | 6 |
| Janus protein-tyrosine kinase 2 | JAK2 | Y1007+Y1008 | ANG II-dependent (AT1-type receptor) modulation of water/salt balance (1, 38) |
175 | −8 | −26 |
| Jun protooncogene-encoded AP1 transcription factor | Jun* | S73 | ANG II-dependent (AT1-type receptor) modulation of water/salt balance (1, 38) |
91 | −24 | −20 |
| Jun protooncogene-encoded AP1 transcription factor | Jun | S63 | ANG II-dependent (AT1-type receptor) modulation of water/salt balance (1, 38) |
199 | 36 | −25 |
| Protein-serine kinase Cβ2 | PKCb2 | T641 | ANG II-dependent (AT1-type receptor) modulation of water/salt balance (1, 38) |
106 | 28 | 36 |
| Src proto-oncogene-encoded protein-tyrosine kinase | Src | Y418 | ANG II-dependent (AT1-type receptor) modulation of water/salt balance (1, 38) |
86 | 44 | −9 |
| Signal transducer and activator of transcription 1 | STAT1 | S727 | Diabetic nephropathy (50) | −33 | 173 | −14 |
| Signal transducer and activator of transcription 3 (acute phase response factor) |
STAT3 | S727 | Mesangial and proximal tubular epithelial cell proliferation; renal fibrosis; glomerular diseases; diabetic nephropathy (33, 36, 50) |
−31 | 37 | 51 |
| Jun NH2 terminus protein-serine kinases [stress-activated protein kinase (SAPK)] 1/2/3 |
JNK* | T183+Y185 | Renal ischemia-reperfusion injury (54) | 125 | −28 | −23 |
| Cyclin-dependent protein-serine kinase 1/2 | CDK1/2 | T161+ T160 | Parenchymal renal diseases (41) | −29 | 85 | −73 |
| Retinoblastoma-associated protein1 | Rb | S780 | Renal tubular cell senescence in renal ischemia- reperfusion injury (27) |
12 | 97 | −41 |
| BclII-antagonist of cell death protein | Bad | S75 | Renal tubular cell death (30) | 16 | −14 | −39 |
| BclII-antagonist of cell death protein | Bad | S91 | Renal tubular cell death (30) | 72 | −33 | −12 |
| Acetyl coenzyme A carboxylase | AcCoA | S80 | Fatty acid synthesis (3); chronic renal failure-induced hyperlipidemia (51) |
−65 | −33 | −49 |
| Insulin receptor | IR | Y999 | Glucose metabolism (2) | 29 | −36 | −17 |
| Insulin receptor substrate 1 | IRS1 | Y612 | Glucose metabolism (2, 11) | 126 | −25 | 31 |
| Insulin receptor substrate 1 | IRS1 | Y1179 | Glucose metabolism (2, 11) | 25 | −36 | −28 |
| Phosphoprotein-enriched in diabetes 15 | PED15 | S116 | Regulates glucose transporters (8) | −75 | 73 | 3 |
AVR, angiotensin-vasopressin receptor; NAVR, non-AVR; ANG II, angiotensin II; AVP, arginine-vasopressin; % CFC, percent change from control; phospho site, phosphorylation site (tracked with specified phospho-site-specific antibodies);
*
Performed with 6 replicas. % CFC ≥20 (bold) and ≤ −20 (italics) are highlighted; repeated-measures ANOVA P < 0.04.